Plasma glucagon-like peptide (GLP) (7-36) amide response to low versus high glycaemic index drinks in Type II diabetic subjects and non-diabetic controls.
| ISRCTN | ISRCTN41341840 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN41341840 |
| Protocol serial number | N0016132030 |
| Sponsor | Department of Health |
| Funder | Hammersmith Hospital NHS Trust (UK) |
- Submission date
- 30/09/2004
- Registration date
- 30/09/2004
- Last edited
- 10/03/2011
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Nutritional, Metabolic, Endocrine
Plain English summary of protocol
Not provided at time of registration
Contact information
Scientific
Nutrition and Dietetics Department
Imperial College
Hammersmith Campus
London
W12 0HS
United Kingdom
| Phone | +44 (0)208 383 5802 |
|---|---|
| JMilton@hhnt.org |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Randomised controlled trial |
| Secondary study design | Randomised controlled trial |
| Scientific title | |
| Study objectives | 1. To investigate the effects of drinks of differing glycaemic index (GI) on plasma GLP-1 concentrations and subsequent metabolic responses to a meal. 2. To determine if a low GI drink will cause a greater increase in postprandial GLP-1 concentrations and result in improved metabolic response compared to a high GI drink or water at a subsequent meal. |
| Ethics approval(s) | Not provided at time of registration |
| Health condition(s) or problem(s) studied | Nutritional, Metabolic, Endocrine: Diabetes |
| Intervention | Not provided at time of registration |
| Intervention type | Other |
| Primary outcome measure(s) |
Diet is the first line treatment for Type 2 diabetes, however the optimal diet to promote good glycaemic control is still debated. GLP-1 is being investigated as an agent for the treatment of diabetes, however it has its shortcomings due to its short half life in humans. A specific food that could be consumed before a meal to stimulate release of GLP-1 and thus improve glycaemic control would be highly beneficial to patients, and potentially have fewer side effects and be less invasive than subcutaneous administration of the hormone. |
| Key secondary outcome measure(s) |
Not provided at time of registration |
| Completion date | 09/09/2007 |
Eligibility
| Participant type(s) | Healthy volunteer |
|---|---|
| Age group | Adult |
| Sex | Not Specified |
| Target sample size at registration | 24 |
| Key inclusion criteria | 1. 12 diabetics and 12 healthy volunteers 2. Ages 30-65 |
| Key exclusion criteria | Not provided at time of registration |
| Date of first enrolment | 10/09/2003 |
| Date of final enrolment | 09/09/2007 |
Locations
Countries of recruitment
- United Kingdom
- England
Study participating centre
W12 0HS
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 01/12/2007 | Yes | No |
